Browse studies

Find your next paid study

10 recruiting studies matching your filters

A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants With Exocrine Pancreatic Insufficiency- EPIC

The purpose of this study is to measure the safety and explore the efficacy of 4 different doses of the new lipase NHS7108 in participants with EPI. In this st…

Exocrine Pancreatic Insufficiency (EPI)Cystic Fibrosis (CF)Pancreatic Enzyme Abnormality+1 more

Estimated

~$10 – $8,750

Aimmune Nestlé Health Science US R&D, LLCNCT07559175

Phase 2

A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine p…

Exocrine Pancreatic Insufficiency (EPI)Cystic Fibrosis (CF)

Estimated

~$10 – $8,750

Anagram Therapeutics, Inc.NCT07450547

Phase 4

Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis

This project uses the Malabsorption Blood Test (MBT) to identify patients with recurrent acute or chronic pancreatitis who have mild to moderate exocrine pancr…

Chronic PancreatitisRecurrent Acute PancreatitisExocrine Pancreatic Insufficiency

Estimated

~$10 – $7,500

Anna Evans PhillipsNCT07418593

Phase 1

Pharmacokinetic and Pharmacodynamic Effects of Dorzagliatin in Pancreatic Insufficient-Cystic Fibrosis: A Randomized Double-blind, Cross-over Trial

This study is designed to determine the pharmacokinetic and pharmacodynamic response of dorzagliatin 50 mg twice daily following 7-day administration in indivi…

Pancreatic InsufficiencyCystic Fibrosis-related Diabetes

Estimated

~$10 – $7,500

Michael R. Rickels, MD, MSNCT06995651

Phase 4

An Open-Label Study On The Effects Of Human Secretin For Injection (CHIROSTIM) On Pancreatic Fluid Composition In Normal Human Volunteer Participants

The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after…

Exocrine Pancreatic InsufficiencyChronic Pancreatitis

Estimated

~$10 – $6,250

Mayo ClinicNCT07285863

Phase 2

Effect of GLP-1 Agonist Therapy on Insulin Secretion in Adults With Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a Randomized, Open-label, Cross-over Trial

Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes t…

Cystic FibrosisPancreatic InsufficiencyAbnormal Glucose Tolerance+1 more

Estimated

~$10 – $6,250

University of PennsylvaniaNCT04731272

Phase 3

A Randomized Controlled Trial to Evaluate the Efficacy of Immobilized Lipase (RELiZORB) During Enteral Nutrition in Patients With Exocrine Pancreatic Insufficiency Secondary to Acute Pancreatitis

This research aims to improve the management of exocrine pancreatic insufficiency (EPI), a condition that can develop after pancreatitis, a painful inflammatio…

Exocrine Pancreatic Insufficiency (EPI)Pancreatitis

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06691893

Phase 4

Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency: the PERT-AP Trial

This study aims to evaluate if a 6-month course of pancrelipase (CREON) treatment improves symptoms of exocrine pancreatic insufficiency (EPI) after an attack …

Exocrine Pancreatic Insufficiency

Estimated

~$10 – $6,250

Ohio State UniversityNCT06477159

Observational

Determination of Beta-cell Responsiveness to the Incretin Hormones GLP-1 and GIP in Cystic Fibrosis

In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D)…

Cystic FibrosisPancreatic Insufficiency

Estimated

~$10 – $6,250

University of PennsylvaniaNCT01851694

The Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform Program (SDS-GPS Program)

The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in t…

Shwachman-Diamond SyndromeSDSIBMF+24 more

Estimated

~$10 – $1,050

Shwachman-Diamond Syndrome Alliance IncNCT06999954